Table 1.
List of active trials in phase 2 or 3 throughout the world that are currently evaluating the efficacy of investigational drugs targeting cytokine release in COVID-19.
| Drug | Study title | Clinical trial identifier | Country | Phase | Status |
|---|---|---|---|---|---|
| Anakinra Emapalumab |
Efficacy and safety of Emapalumab and Anakinra in reducing hyperinflammation and respiratory distress in patients with COVID-19 | NCT04324021 | Italy | Phase 2/3 | Recruiting |
| Anakinra Tocilizumab |
Personalized Immunotherapy for SARS-CoV-2 associated with organ dysfunction (ESCAPE) | NCT04339712 | Greece | Phase 2 | Recruiting |
| Anakinra Siltuximab Tocilizumab |
Treatment of COVID-19 patients with Anti-interleukin drugs (COV-AID) | NCT04330638 | Belgium | Phase 3 | Recruiting |
| Anakinra | Trial evaluating efficacy of Anakinra in patients with COVID-19 Infection | NCT04341584 | France | Phase 2 | Not yet recruiting |
| Sarilumab Azithromycin Hydrooxychloro-quine |
Study of immune modulatory drugs and other treatments in COVID-19 patients: Sarilumab, azithromycin, hydroxychloroquine trial (CORIMUNO-VIRO) | NCT04341870 | France | Phase 2/3 | Recruiting |
| Sarilumab | Evaluation of efficacy and safety of Sarilumab in patients hospitalized with COVID-19 | NCT04315298 | United States | Phase 2/3 | Recruiting |
| Sarilumab | Sarilumab COVID-19 | NCT04327388 | Canada | Phase 2/3 | Recruiting |
| Sarilumab Tocilizumab |
Anti-IL6 treatment of serious COVID-19 disease with threatening respiratory failure (TOCIVID) | NCT04322773 | Denmark | Phase 2 | Recruiting |
| Siltuximab | An observational case-control study of the use of Siltuximab in ARDS patients diagnosed with COVID-19 infection. | NCT04322188 | Italy | – | Recruiting |
| Siltuximab Methylprednisolone |
Efficacy and safety of Siltuximab vs corticosteroids in hospitalized patients with COVID-19 pneumonia | NCT04329650 | Spain | Phase 2 | Recruiting |
| Baricitinib Sarilumab Hydroxychloroquine |
Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia (CCAP) | NCT04345289 | Denmark | Phase 3 | Not yet recruiting |
| Baricitinib | Baricitinib in symptomatic patients infected by COVID-19: an open-label, pilot study (BARI-COVID). | NCT04320277 | Italy | Phase 3 | Recruiting |
| Baricitinib Sarilumab |
Treatment of moderate to severe coronavirus disease (COVID-19) in hospitalized patients. | NCT04321993 | Canada | Phase 2 | Not yet recruiting |
| Baricitinib | Safety and efficacy of Baricitinib for COVID-19 | NCT04340232 | USA | Phase 2/3 | Not yet recruiting |
| Leronlimab | Study to evaluate the efficacy and safety of Leronlimab for mild to moderate COVID-19 | NCT04343651 | United States | Phase 2 | Recruiting |
| Leronlimab | Study to evaluate the efficacy and safety of Leronlimab with severe to critical coronavirus disease 2019 (COVID-19). | NCT04347239 | United States | Phase 2 | Recruiting |